Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie IncfiledCriticalAbbvie Inc
Priority to MYPI99002107ApriorityCriticalpatent/MY116032A/en
Publication of MY116032ApublicationCriticalpatent/MY116032A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
A LIQUID PHARMACEUTICAL COMPOSITION PROVIDING IMPROVED ORAL BIOAVAILABILITY IS DISCLOSED FOR COMPOUNDS WHICH ARE INHIBITORS OF HIV PROTEASE.IN PARTICULAR, THE COMPOSITION COMPRISES A SOLUTION IN A PHARMACEUTICALLY ACCEPTABLE ORGANIC SOLVENT OF (A) THE HIV PROTEASE INHIBITOR AND, OPTIONALLY, (B) A SURFACTANT. THE COMPOSITION CAN OPTIONALLY BE ENCAPSULATED IN EITHER HARD GELATIN CAPSULES OR SOFT ELASTIC CAPSULES (SEC).
MYPI99002107A1999-05-271999-05-27Liquid composition comprising an hiv protease inhibitor and a, c12-c18 fatty acid
MY116032A
(en)
Liquid immediate release pharmaceutical formulation comprising an acid addition salt of a substituted azetidine derivative compound and a pharmaceutically acceptable diluent or carrier useful for the treatment or prevention of thrombosis.
"soluble stable pharmaceutical composition for the administration of hiv protease inhibitors and a process for the preparation of concentrated pharmaceutical compositions for the administration of hiv protease inhibitors."
Bis-amino acid sulfonamides containing n-terminally a substituted benzyl group as hiv protease inhibitors, pharmaceutical compositions comprising thereof and their use